Drug Trial Radar · NCT07660198
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Dec 2, 2027
Study completion Dec 2, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 months, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in children when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. It will also assess how the new vaccine works in comparison to the one that is currently in use. To measure how the new pneumococcal vaccine compares to the current one, blood samples will be used to measure the body's ability to create proteins to fight those germs. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to children. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae This study is seeking participants who: * Are children aged 15 months to 18 years. * May or may not have received any doses of pneumococcal conjugate vaccine (PCV) in the past. The study will be conducted in the United States, Puerto Rico, and other countries. Participants will be assigned to 1 of 3 groups based on age: Group 1: 15 months to less than 2 years (about 300 participants) Group 2: 2 years to less than 5 years (about 300 participants) Group 3: 5 years to less than 18 years (about 600 participants) Within each group, participants will be assigned by chance in a 2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) or 20vPnC, given in the arm or thigh. This means that for every 3 participants, about 2 will receive PG4 and about 1 will receive 20vPnC. Each participant will take part in the study for approximately 6 months. During this time, each participant will visit a clinic 2 times (visit 1 for vaccination and visit 2 to follow up) and will be contacted via telephone once (for a 6 month follow up). At the study clinic visits, participants will have their blood drawn and be asked if they have experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine. During the 6-month follow-up contact, participants will be asked about any further side effects.
Conditions
- Pneumococcal Disease
Interventions
PG4Biological
Multivalent Pneumococcal Vaccine
20-valent pneumococcal conjugate vaccine (20vPnC)Biological
20-valent pneumococcal conjugate vaccine (20vPnC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Local Reactions Within 7 Days After VaccinationTime frame: Within 7 days after Vaccination
- Percentage of Participants With Systemic Events Within 7 Days after VaccinationTime frame: Within 7 days after Vaccination
- Percentage of Participants With Adverse Events (AEs)Time frame: From Vaccination to 1 month after Vaccination
- Percentage of Participants With Serious Adverse Events (SAEs)Time frame: From Vaccination to 6 months after Vaccination
- GMCs of serotype-specific IgG concentrationsTime frame: 1 month after vaccination
- GMTs of serotype-specific OPA titersTime frame: 1 month after vaccination
Locations
77 sites in 4 countries. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics, LLC Birmingham Pediatric Associates
Birmingham, Alabama · Recruiting
UAB Child Health Research Unit (CHRU)
Birmingham, Alabama · Recruiting
Lakeview Clinical Research, LLC
Guntersville, Alabama · Recruiting
Apex Research Group
Fair Oaks, California · Recruiting
Orange County Research Institute
Ontario, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Riveldi and Associates
Miami Lakes, Florida · Recruiting
Indago Research & Health Center, Inc
Miami Lakes, Florida · Recruiting
South Tampa Center for Advanced Healthcare- USF Health
Tampa, Florida · Recruiting
USF Health
Tampa, Florida · Recruiting
USF Health Department of Pediatrics The Chalsty Clinics at the Curran Children's Health Center (CMS)
Tampa, Florida · Recruiting
Children's Health Center
Tampa, Florida · Recruiting
Medical Research Partners
Ammon, Idaho · Recruiting
Bingham Memorial Hospital
Blackfoot, Idaho · Recruiting
ASR, LLC
Boise, Idaho · Recruiting
Kentucky Pediatric/ Adult Research
Bardstown, Kentucky · Recruiting
Avacare
Covington, Louisiana · Recruiting
Velocity Clinical Research, Lafayette
Lafayette, Louisiana · Recruiting
LSU Health Shreveport Clinical Trials Office
Shreveport, Louisiana · Recruiting
Ochsner/LSU Health Shreveport - Progressive Pediatrics
Shreveport, Louisiana · Recruiting
Ochsner LSU Health Shreveport Ambulatory Care Center
Shreveport, Louisiana · Recruiting
Ochsner/LSU Health Shreveport Academic Medical Center
Shreveport, Louisiana · Recruiting
Pediatric Associates of Fall River
Fall River, Massachusetts · Recruiting
Michigan Center of Medical Research
Bingham Farms, Michigan · Recruiting
Clinical Research Institute, Inc.
Minneapolis, Minnesota · Recruiting
Midwest Children's Health Research Institute
Lincoln, Nebraska · Recruiting
Midwest Children's Health Research Institute
Lincoln, Nebraska · Recruiting
Midwest Children's Health Research Institute
Lincoln, Nebraska · Recruiting
Midwest Children's Health Research Institute
Lincoln, Nebraska · Recruiting
Child Health Care Associates
East Syracuse, New York · Recruiting
Corning Center for Clinical Research
Horseheads, New York · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
Cincinnati Children's Hospital Medical Center Investigational Drug Services
Cincinnati, Ohio · Recruiting
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio · Recruiting
Pediatric Associates of Mt. Carmel
Cincinnati, Ohio · Recruiting
Dayton Clinical Research
Dayton, Ohio · Recruiting
Senders Pediatrics
South Euclid, Ohio · Recruiting
Tribe Clinical Research LLC. at Parkside Pediatrics Five Forks
Simpsonville, South Carolina · Recruiting
Pediatric Clinical Trials of Tennessee, LLC
Tullahoma, Tennessee · Recruiting
South Texas Clinical Research
Corpus Christi, Texas · Recruiting
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.